PMID- 31565874
OWN - NLM
STAT- MEDLINE
DCOM- 20200513
LR  - 20200513
IS  - 2093-5978 (Electronic)
IS  - 2093-596X (Print)
IS  - 2093-596X (Linking)
VI  - 34
IP  - 3
DP  - 2019 Sep
TI  - Nonalcoholic Fatty Liver Disease and Diabetes: An Epidemiological Perspective.
PG  - 226-233
LID - 10.3803/EnM.2019.34.3.226 [doi]
AB  - Nonalcoholic fatty liver disease (NAFLD) is thought to stem from the body's 
      inability to store excess energy in adipocytes; as such, it is commonly viewed as 
      the hepatic manifestation of metabolic syndrome. The pathogenesis of NAFLD 
      involves ectopic fat accumulation, which also takes place in the liver, muscle 
      and visceral fat. NAFLD is rapidly becoming more widespread in Korea, with an 
      estimated prevalence of 30% in adults. Type 2 diabetes mellitus (T2DM) and NAFLD 
      share insulin resistance as a common pathophysiological mechanism, and each of 
      these two diseases affects the development of the other. Recent studies have 
      suggested that NAFLD is often present as a comorbidity in T2DM patients. The 
      mutual interrelationship between these conditions is shown by findings suggesting 
      that T2DM can exacerbate NAFLD by promoting progression to nonalcoholic 
      hepatosteatosis or fibrosis, while NAFLD causes the natural course of diabetic 
      complications to worsen in T2DM patients. It remains unknown whether one disease 
      is the cause of the other or vice versa. In this review, I would like to discuss 
      current epidemiological data on the associations between NAFLD and T2DM, and how 
      each disease affects the course of the other.
CI  - Copyright (c) 2019 Korean Endocrine Society.
FAU - Rhee, Eun Jung
AU  - Rhee EJ
AUID- ORCID: 0000-0002-6108-7758
AD  - Department of Endocrinology and Metabolism, Kangbuk Samsung Hospital, 
      Sungkyunkwan University School of Medicine, Seoul, Korea. hongsiri@hanmail.net.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Korea (South)
TA  - Endocrinol Metab (Seoul)
JT  - Endocrinology and metabolism (Seoul, Korea)
JID - 101554139
SB  - IM
MH  - Diabetes Mellitus, Type 1/complications/*epidemiology
MH  - Diabetes Mellitus, Type 2/complications/*epidemiology
MH  - Fibrosis/complications/epidemiology
MH  - Humans
MH  - Non-alcoholic Fatty Liver Disease/complications/*epidemiology
MH  - Republic of Korea/epidemiology
MH  - Risk Factors
PMC - PMC6769345
OTO - NOTNLM
OT  - Diabetes mellitus, type 2
OT  - Epidemiology
OT  - Insulin resistance
OT  - Non-alcoholic fatty liver disease
COIS- No potential conflict of interest relevant to this article was reported.
EDAT- 2019/10/01 06:00
MHDA- 2020/05/14 06:00
PMCR- 2019/09/01
CRDT- 2019/10/01 06:00
PHST- 2019/08/25 00:00 [received]
PHST- 2019/09/05 00:00 [revised]
PHST- 2019/09/09 00:00 [accepted]
PHST- 2019/10/01 06:00 [entrez]
PHST- 2019/10/01 06:00 [pubmed]
PHST- 2020/05/14 06:00 [medline]
PHST- 2019/09/01 00:00 [pmc-release]
AID - 34.226 [pii]
AID - 10.3803/EnM.2019.34.3.226 [doi]
PST - ppublish
SO  - Endocrinol Metab (Seoul). 2019 Sep;34(3):226-233. doi: 10.3803/EnM.2019.34.3.226.